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 The geriatric assessment (GA) is defined as a multidimensional, interdisciplinary diagnostic process focusing on determining 
an older person’s medical, psychosocial, and functional capabilities that are not identified by routine evaluation. There is 
more and more data on the benefits of the GA in the evaluation and management process of older patients with cancer. 
It allows for the development of an individual cancer treatment plan resulting in less postoperative complications, redu-
ced treatment toxicity, improved quality of life and very often without compromising survival. However, the relationship 
between specific domains of the GA and post-treatment medical outcomes, functional status and quality of life remains 
unknown. Moreover, there is still no consensus over what the “golden standard” GA should look like, which tools should 
be included and what cut-off should be used. This is still an active area of research. However, there is no doubt that under-
standing the health status of an older patient with cancer should be as important as cancer staging and tumour biology.
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As has been mentioned in the previous articles, older adults 
are a heterogeneous group having varying degrees of co-
morbidities, functional reserves, cognitive impairments and 
social support [1]. Therefore, chronological age alone and the 
routine format of medical history, physical examination, bio-
chemistry and imaging tests often do not provide adequate 
information needed for optimal and tailored treatment. Many 
older adults have unidentified, uncommunicated, and there-
fore unaddressed aging-related conditions that are associated 
with morbidity and early mortality [2]. To help guide treatment 
decisions the geriatric assessment (GA) was introduced, a mile-
stone in the field of geriatrics. Moreover, at present, cancer 
treatment for older patients is very often planned based on 
extrapolations of evidence derived from clinical trials in which 
younger patients or fit older patients enrolled [3]. 
The GA is defined as a multidimensional, interdisciplinary 
diagnostic process focusing on determining an older perso-
n’s medical, psychosocial, and functional capabilities. In turn, 
the term comprehensive geriatric assessment (CGA) refers to 
a GA which also includes a plan for the further management 
of identified problems. Therefore, the main goal of the CGA in 
older cancer patients is to provide a comprehensive health 
appraisal to guide targeted interventions and appropriate 
cancer treatment selection [4].
The GA was initially developed and validated in the general 
older population for detecting vulnerability and aging-rela-
ted issues that were associated with mortality [5]. However, 
numerous studies, though not all, have proved its usefulness 
equally in cancer patients:
• The GA allows the determination of a baseline health 
status, monitoring of changes and a diagnostic of the 
frailty status, which is an exponent of biological old age;
• The GA can identify age-related areas of vulnerability that 
can be missed in routine clinical evaluation in up to 50% 
of patients [6]. These impairments concern physical func-
tioning and nutritional status, but also very often geriatric 
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syndromes such as: dementia, delirium, depression, incon-
tinence, sarcopenia, osteoporosis/spontaneous fractures 
which are independent risk factors of worse outcome [6]. 
Routinely used oncological tools like the Eastern Coopera-
tive Oncology Group (ECOG) or the Karnofsky performance 
status have been shown to poorly reflect functional impa-
irment in older patients with cancer. In patients with an 
ECOG score <2 almost 40% of patients were dependent 
on some form of instrumental activities for daily living [7];
• Performing the GA can change treatment decisions for up 
to 50% of older patients [8, 9]. In these studies, in the case 
of up to 28% of patients, the treatment was intensified 
and in case of up to 37%, the treatment intensity was 
reduced [10, 11];
• The GA can identify areas for further rehabilitative actions 
such as: review of diet and nutrition, physical performan-
ce, psychological support, medication review and social 
support. In some studies, applying the GA reduced the 
number of treatment related complications. Other studies 
have not confirmed this, but in case of high-risk patients 
its use allowed the completion of the cancer treatment 
with fewer treatment modifications [12];
• The GA can predict survival of and adverse events during 
cancer treatment. Thus, it may assist clinical decision-making.
• The GA can improve patient physician communication 
about aging-related concerns and their influence on the 
treatment outcome [13]. A practical and convenient GA 
summary with recommendations for aging-sensitive in-
terventions improves patient-cantered outcomes and 
patient satisfaction.
Biological age does not correspond with the chronological 
age. Therefore, it is difficult to arbitrarily set the level of age at 
which the GA should be implemented. Most of the guidelines 
recommend it at the age of 70 years. However, in our opinion, 
the age should be set at the level of 65 years in Polish society. 
It also should be performed in younger patients identified in 
screening tests [14]. 
The GA consists of several domains evaluating: functional 
status, mobility/falls, cognitive level, mood, comorbidity, poly-
pharmacy, fatigue and social support. At present, there are se-
veral well-validated tools available. Table I presents an overview 
of the different tests with literature-based cut-offs that may be 
used in the GA process. There has been no consensus about 
which tools should be included in the GA and until now there 
have been no studies showing the superiority of one specific 
tool over another. Therefore, the choice of score might rely on 
local preferences, the aim of the tool and present resources. 
The number of incorporated GA domains has a great in-
fluence on the diagnosis of frailty and on adequate risk as-
sessment as we showed in one previous study. The summary 
deficit score based on the GA consisting of functional, mobility, 
cognitive, depression, nutritional, co-morbidity, polypharma-
cy, and social support questionnaires was the most accurate 
predictor of post-operative complications in comparison to 
models with less incorporated domains [33].
In turn, two large prospective studies – Cancer and Aging 
Research Group (CARG) and Chemiotherapy Risk Assessment 
Scale for High-Age Patients (CRASH) – identified which para-
meters of the GA were capable of predicting severe chemothe-
rapy-related complications in a heterogeneous cancer popula-
tion (tab. II) [33, 34]. Both scores revealed their superiority over 
the Karnofsky performance status or other classic oncological 
evaluation tools. They can also help determine the risks and 
benefits of treatment, promoting shared decision-making. 
High-risk patients can be monitored closely. A randomized 
study of GA-directed therapy for older patients with advanced 
lung cancer demonstrated reduced toxic effects of treatment 
and less treatment discontinuation in the GA group [35]. 
In case of radiotherapy the literature is still scarce. Spyro-
poulou et al. observed higher risk of not completing radiation 
in the case of impaired score on a VES-13 (screening frailty 
tool) [36].
There are various models of the GA. It can be performed 
within a geriatric ward with a specialized geriatric team. Six 
meta-analyses showed that this model is the most effective 
method with lower mortality, less institutionalization, and less 
functional decline compared with a standard ward [37–39]. In 
the case of the model with a specialized geriatric team that ap-
Table I. Glossary of the most common tools used in the geriatric assessment process
Test Number of items Range Cut-off score





IADL (Lawton Instrumental Activities of Daily Living) [16] 8 0–8 ≤7
The Duke OARS Assessment of IADL
[17]
6 12 <9
Barthel scale [18] 10 0–100 ≤60
Self reported number of falls within different time frames
1 0–∞
>2 within last 6 
months




Gait speed [20] 1 0–∞
155
plies the GA in non-geriatric wards, one meta-analysis could not 
show significant improvement in the outcome of the patients. 
However, the main reason for this was the low adherence rate 
to the geriatric team’s recommendations [40]. In turn, joint ge-
riatric and specialized care on the ward is gaining in popularity 
and showing promising results in more and more studies [41].
In conclusion, all physicians treating older patients with 
cancer should include some form of geriatric assessment in 
their clinical practise. Multiple organizations including the 
International Society of Geriatric Oncology, the National Com-
prehensive Cancer Network and the European Organization for 
the Research and Treatment of Cancer recommend the use of 
the GA prior to the initiation of cancer treatment. However, it is 
still not routinely performed due to a false belief in its comple-
xity and time consumption. Various forms of the GA allow its 
incorporation in busy clinical settings. The use of a given tool 
and cut-off is, in light of current research results, not as impor-
tant as the incorporation of the following domains: functional 
status, mobility/falls, cognition function, depression/anxiety, 
comorbidities, polypharmacy, nutritional status and social 
support. The more domains included, the more adequate the 
risk assessment that will be achieved. 
Test Number of items Range Cut-off score
Charlson Comorbidity Scale [21]
Comorbidity
19 0–37 ≥3
Cumulative Illness Rating Scale (CIRS-G) [22] 13 0–52 >4
Geriatric Depression Scale [23] Depression 15 0–15 >5




Montreal Cognitive Assessment [25] 7 0–30 <26








Clock Drawing Test (CDT-test) [28] 7 0–7 ≤4
Mini Nutritional Assessment [29] Nutritional 
assessment
6 0–14 <12
MNA full [29] 18 0–30 <24
Number of medications Toxicity risk 1 0–∞ >4







RAND MOS Social Support Scale [31] Social 
Support
19 0–5 <4
Table II. CARG and CRASH score
CARG score (Cancer and Aging Research Group) CRASH (Chemiotherapy Risk Assessment Scale for High-Age Patients)
Variable Score Variable Points
0 1 2
– Age ≥72 years old
– Cancer type (gastrointestinal or genitourinary)
– Chemiotherapy dosing (standard dosing)
– Number of chemiotherapy drugs (polychemitherapy)
– Hemoglobin (<11 g/dL in males, 10 g/dL in females)
– Creatinine clearance (<34 mL/min)
– Hearing (fair or worse)
– Number of falls in the past 6 months (one or more)
– Take medications with some help/ unable
– Walking one block, somewhat limited/ limited a lot
– Decreased social activity because of physical/









































BP – blood pressure, Chemotox – toxicity of the chemotherapy regimen, ECOG PS – Eastern Cooperative Oncology Group performance status, IADL – Instrumental Activities of 
Daily Living, LDH – lactate dehydrogenase, MMS – Mini Mental Health Status, MNA – Mini Nutritional Assessment
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Frailty screening tools (the topic of one of the next artic-
les) are useful. These are simple and quick tools to identify 
fit older patients who do not require additional assessments 
or interventions. However, in the case of older patients with 
cancer, qualified for abdominal surgery, recognised as high-risk 
surgery, their predictive value, as the only assessment tool, is 
currently insufficient. 
The arguments raised about the time-consuming nature 
of the GA/CGA are absurd, particularly when one considers the 
time and resources required to treat complications. Therefore, 
understanding the health status of an older patient with cancer 
should be as important as cancer staging and tumour biology. 
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